Blog
RSS FeedPosted by Michael Wonder on 16 Mar 2022
Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency
16 March 2022 - NICE has published evidence-based recommendations on the use of dostarlimab (Jemperli) for the treatment of adults ...
Posted by Michael Wonder on 16 Mar 2022
Life-extending injection for blood cancer available on the NHS
15 March 2022 - A life-extending injection for a fatal form of blood cancer will be available to around 350 ...
Posted by Michael Wonder on 09 Mar 2022
NICE unable to provide guidance on a new use of lenalidomide
9 March 2022 - NICE is unable to make a recommendation on the use of lenalidomide for the treatment of patients ...
Posted by Michael Wonder on 08 Mar 2022
NICE yet to support the use of pralsetinib on the NHS
3 March 2022 - NICE publishes appraisal consultation document for a new medicine for certain patients with non-small-cell lung cancer. ...
Posted by Michael Wonder on 08 Mar 2022
NICE draft guidance does not recommend pembrolizumab plus chemotherapy for triple negative breast cancer
8 March 2022 - The evidence showed that pembrolizumab plus chemotherapy is more effective than paclitaxel or nab-paclitaxel, although the ...
Posted by Michael Wonder on 04 Mar 2022
Hundreds of patients to benefit from revolutionary lung cancer drug on the NHS
3 March 2022 - A revolutionary targeted drug for lung cancer will be made available to anyone who is eligible, ...
Posted by Michael Wonder on 03 Mar 2022
Over 500 people a year can access a new life extending lung cancer treatment after NICE recommends its use within the Cancer Drugs Fund
3 March 2022 - An innovative life-extending drug for treating mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults ...
Posted by Michael Wonder on 25 Feb 2022
NICE draft guidance recommends tucatinib for advanced breast cancer
25 February 2022 - Taken as two 150 mg tablets twice daily together with anti-cancer medicines trastuzumab and capecitabine, tucatinib ...
Posted by Michael Wonder on 24 Feb 2022
Once a day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
24 February 2022 - The 20th cancer treatment to go through the Cancer Drugs Fund following a period of managed access ...
Posted by Michael Wonder on 10 Feb 2022
New life-extending drug for advanced womb cancer to be rolled out on the NHS
8 February 2022 - A 30 minute treatment, the first of its kind for advanced womb cancer, is being rolled ...
Posted by Michael Wonder on 09 Feb 2022
NICE terminates yet another appraisal of daratumumab
9 December 2022 - NICE has attempted to appraise daratumumab six times; three have had to be terminated. ...
Posted by Michael Wonder on 09 Feb 2022
More than 100 people a year in England could benefit from new endometrial cancer treatment within the Cancer Drugs Fund
8 February 2022 - Innovative new drug for treating endometrial cancer in adults recommended by NICE as an option for use ...
Posted by Michael Wonder on 08 Feb 2022
NICE misses golden opportunity to enhance access to innovative cancer drugs
7 February 2022 - Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity ...
Posted by Michael Wonder on 07 Feb 2022
Not so NICE: cancer patients miss out on innovative new treatments
7 February 2022 - Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes ...
Posted by Michael Wonder on 02 Feb 2022
Olaparib a 'no go' for patients with breast cancer in England
2 February 2022 - Olaparib has been approved to treat patients with BRCA mutation positive HER2 negative metastatic breast cancer after ...